US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Emera Inc.

50.08

-1.7000-3.28%

Post-market: 51.050.9700+1.94%19:30 EDT

Volume:487.92K

Turnover:24.66M

Market Cap:15.31B

PE:22.46

High:51.91

Open:51.91

Low:50.03

Close:51.78

52wk High:55.49

52wk Low:45.77

Shares:305.78M

Float Shares:305.78M

Volume Ratio:1.75

T/O Rate:0.16%

Dividend:2.12

Dividend Rate:4.23%

EPS(TTM):2.23

EPS(LYR):2.47

ROE:7.56%

ROA:2.91%

PB:1.63

PE(LYR):20.32

Loading ...

Overview Company News Filings

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN)

Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe

MT Newswires Live

Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial

Emera (EMA) Receives a Hold from Barclays

Press Release: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

Emera Q1 Adjusted Earnings, Revenue Rise

MT Newswires Live

Emera reports Q1 adjusted EPS $1.37 vs. $1.28 last year

Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20

MT Newswires Live

Emera Q1 Adj. EPS $1.00 Beats $0.89 Estimate

Benzinga Earnings

Press Release: Emera Reports 2026 First Quarter Financial Results

Calendar of U.S. Earnings Expected in the Week Ahead

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Press Release: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/EMA/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":50.08,"timestamp":1787342400000,"preClose":51.78,"halted":0,"volume":487921,"hourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"delay":0,"changeRate":-0.03283120896098885,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"Market Closed","change":-1.7,"latestTime":"08-21 16:00:00 EDT","open":51.91,"high":51.91,"low":50.025,"amount":24657789.365397997,"amplitude":0.036404,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":51.78,"dividendRate":0.042108,"preHourTrading":{"tag":"盘前","latestPrice":52.07,"preClose":51.78,"latestTime":"09:00 EDT","volume":9,"amount":465.57171,"timestamp":1787317237082,"change":0.29,"changeRate":0.005601,"amplitude":0.030707},"postHourTrading":{"tag":"盘后","latestPrice":51.05,"preClose":50.08,"latestTime":"19:30 EDT","volume":175258,"amount":8787992.254964,"timestamp":1787355005298,"change":0.97,"changeRate":0.019369,"amplitude":0.019369},"volumeRatio":1.7497389305446422,"impliedVol":0.0649,"impliedVolPercentile":0.1633},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":305783111,"roa":"2.91%","roe":"7.56%","lyrEps":2.465138,"volumeRatio":1.7497389305446422,"shares":305783111,"dividePrice":2.118906,"high":51.91,"amplitude":0.036404,"preClose":51.78,"low":50.025,"week52Low":45.77,"pbRate":"1.63","psRate":"2.36","week52High":55.49,"institutionHeld":0,"latestPrice":50.08,"eps":2.229761,"divideRate":0.04231,"volume":487921,"delay":0,"ttmEps":2.229761,"open":51.91,"prevYearClose":49.24,"prevWeekClose":51.51,"prevMonthClose":53.89,"prevQuarterClose":53.02,"fiveDayClose":51.51,"twentyDayClose":54.95,"sixtyDayClose":53.63,"dividendPayoutRate":0.8394110571990734,"dividendFrequency":"Q","dividendGrowthYears":0,"fiveYearAvgDividendRate":0.04206805783252231},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"EMA","fiscalQuarterEnding":"2026/06","expectedEps":0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.5},{"date":"2026-08-03","symbol":"EMA","amount":0.7325,"announcedDate":"2026-07-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"CAD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"market":"US","date":"2026-05-08","symbol":"EMA","fiscalQuarterEnding":"2026/03","expectedEps":0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":1},{"date":"2026-05-01","symbol":"EMA","amount":0.7325,"announcedDate":"2026-04-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"CAD","dateTimestamp":1777608000000,"payDate":"2026-05-15"},{"market":"US","date":"2026-02-23","symbol":"EMA","fiscalQuarterEnding":"2025/12","expectedEps":0.43,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771822800000,"reportTimeType":"pre","actualEps":0.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-28","recordDate":"2016-11-01","paymentDate":"2016-11-15","value":0.3880294,"currency":"USD"},{"executeDate":"2025-08-01","recordDate":"2025-08-01","paymentDate":"2025-08-15","value":0.725,"currency":"CAD"},{"executeDate":"2025-10-31","recordDate":"2025-10-31","paymentDate":"2025-11-14","value":0.7325,"currency":"CAD"},{"executeDate":"2026-01-30","recordDate":"2026-01-30","paymentDate":"2026-02-13","value":0.7325,"currency":"CAD"},{"executeDate":"2026-05-01","recordDate":"2026-05-01","paymentDate":"2026-05-15","value":0.7325,"currency":"CAD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1778299200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2026-08-21","current":22.459806,"percent":0.843648,"low":16.637027,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"high":22.07626,"avg":19.793468,"sd":1.503181,"marketCap":15955602988.26},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78},{"date":"2025-07-18","current":19.592532,"twenty":19.308216,"median":19.502499,"eighty":19.712577,"marketCap":13439260670.95},{"date":"2025-07-25","current":20.116937,"twenty":19.317694,"median":19.614646,"eighty":19.767545,"marketCap":13920070443.21},{"date":"2025-08-01","current":20.552889,"twenty":19.356234,"median":19.663612,"eighty":19.931816,"marketCap":14004388886.88},{"date":"2025-08-08","current":20.884591,"twenty":19.383402,"median":19.706259,"eighty":20.124519,"marketCap":14315223696.17},{"date":"2025-08-15","current":20.686356,"twenty":19.389088,"median":19.714157,"eighty":20.375981,"marketCap":14241020029.57},{"date":"2025-08-22","current":21.111677,"twenty":19.401724,"median":19.753645,"eighty":20.511821,"marketCap":14434555399.62},{"date":"2025-08-29","current":20.468969,"twenty":19.420679,"median":19.785235,"eighty":20.581071,"marketCap":14130173597.74},{"date":"2025-09-05","current":20.484722,"twenty":19.429525,"median":19.883167,"eighty":20.585711,"marketCap":14060435241.25},{"date":"2025-09-12","current":20.283088,"twenty":19.441529,"median":20.015847,"eighty":20.549566,"marketCap":13928376571.28},{"date":"2025-09-19","current":19.923928,"twenty":19.461747,"median":20.073945,"eighty":20.542062,"marketCap":13714455884.59},{"date":"2025-09-26","current":20.585539,"twenty":19.495865,"median":20.087756,"eighty":20.542062,"marketCap":14040465233.16},{"date":"2025-10-03","current":21.108526,"twenty":19.558414,"median":20.183278,"eighty":20.617044,"marketCap":14341364686.36},{"date":"2025-10-10","current":21.127429,"twenty":19.601378,"median":20.281209,"eighty":20.758818,"marketCap":14318469638.17},{"date":"2025-10-17","current":21.666169,"twenty":19.623491,"median":20.300416,"eighty":20.797254,"marketCap":14653790731.95},{"date":"2025-10-24","current":21.757535,"twenty":19.646868,"median":20.374454,"eighty":20.916344,"marketCap":14770054950.94},{"date":"2025-10-31","current":21.360568,"twenty":19.663296,"median":20.386244,"eighty":21.06631,"marketCap":14513331426.12},{"date":"2025-11-07","current":21.272354,"twenty":19.674036,"median":20.41226,"eighty":21.097184,"marketCap":14296037747.86},{"date":"2025-11-14","current":17.374062,"twenty":19.601378,"median":20.386244,"eighty":21.06631,"marketCap":14568586353.81},{"date":"2025-11-21","current":17.212836,"twenty":19.441529,"median":20.374454,"eighty":21.041735,"marketCap":14368588864.66},{"date":"2025-11-28","current":17.407331,"twenty":19.394143,"median":20.301992,"eighty":21.030393,"marketCap":14577653448.13},{"date":"2025-12-05","current":16.921093,"twenty":19.311375,"median":20.282148,"eighty":21.003928,"marketCap":14257439118.84},{"date":"2025-12-12","current":16.693329,"twenty":19.18059,"median":20.230664,"eighty":20.983135,"marketCap":14234564864},{"date":"2025-12-19","current":17.167393,"twenty":17.900621,"median":20.102346,"eighty":20.957301,"marketCap":14657419004.37},{"date":"2025-12-26","current":17.216186,"twenty":17.458514,"median":20.073945,"eighty":20.944699,"marketCap":14789996894.17},{"date":"2026-01-02","current":17.370269,"twenty":17.373303,"median":20.0392,"eighty":20.932097,"marketCap":14871263471.89},{"date":"2026-01-09","current":17.43447,"twenty":17.368214,"median":19.923928,"eighty":20.903742,"marketCap":14773589152.84},{"date":"2026-01-16","current":17.439606,"twenty":17.353836,"median":19.83736,"eighty":20.887161,"marketCap":14748903694.51},{"date":"2026-01-23","current":17.57828,"twenty":17.358457,"median":19.76786,"eighty":20.862056,"marketCap":14967122519.73},{"date":"2026-01-30","current":17.452446,"twenty":17.36616,"median":19.731531,"eighty":20.822459,"marketCap":15149245081.41},{"date":"2026-02-06","current":17.639913,"twenty":17.358457,"median":19.706259,"eighty":20.792844,"marketCap":15150466223.22},{"date":"2026-02-13","current":17.632209,"twenty":17.329694,"median":19.687304,"eighty":20.780241,"marketCap":15197950382.19},{"date":"2026-02-20","current":18.01228,"twenty":17.336884,"median":19.662032,"eighty":20.776461,"marketCap":15461241242.05},{"date":"2026-02-27","current":19.370854,"twenty":17.349212,"median":19.603589,"eighty":20.77079,"marketCap":15419204876.87},{"date":"2026-03-06","current":19.860551,"twenty":17.357687,"median":19.614646,"eighty":20.758818,"marketCap":15772457447.89},{"date":"2026-03-13","current":20.172176,"twenty":17.364105,"median":19.663612,"eighty":20.731723,"marketCap":16126249798.12},{"date":"2026-03-20","current":19.982975,"twenty":17.371786,"median":19.706259,"eighty":20.697698,"marketCap":15868293252.05},{"date":"2026-03-27","current":19.866116,"twenty":17.374599,"median":19.676248,"eighty":20.661152,"marketCap":15623406729.11},{"date":"2026-04-02","current":20.186088,"twenty":17.375919,"median":19.706259,"eighty":20.620195,"marketCap":15797694590.77},{"date":"2026-04-10","current":20.433719,"twenty":17.383333,"median":19.710303,"eighty":20.603182,"marketCap":16095943521.79},{"date":"2026-04-17","current":20.225489,"twenty":17.405284,"median":19.739002,"eighty":20.583555,"marketCap":16062393790.34},{"date":"2026-04-24","current":20.11598,"twenty":17.412759,"median":19.756565,"eighty":20.571074,"marketCap":16011506016.84},{"date":"2026-05-01","current":20.349038,"twenty":17.435497,"median":19.769087,"eighty":20.551228,"marketCap":16279588937.86},{"date":"2026-05-08","current":20.003663,"twenty":17.442174,"median":19.801031,"eighty":20.543322,"marketCap":15972071463.03},{"date":"2026-05-15","current":20.526748,"twenty":17.453473,"median":19.863334,"eighty":20.551228,"marketCap":15993082457.11},{"date":"2026-05-22","current":20.821212,"twenty":17.457768,"median":19.873689,"eighty":20.574777,"marketCap":16159791825.34},{"date":"2026-05-29","current":20.784047,"twenty":17.458514,"median":19.874498,"eighty":20.606796,"marketCap":16109213261.77},{"date":"2026-06-05","current":20.455276,"twenty":17.46015,"median":19.931505,"eighty":20.606796,"marketCap":15744335184.44},{"date":"2026-06-12","current":20.798341,"twenty":17.481546,"median":19.990575,"eighty":20.612514,"marketCap":15890994194.64},{"date":"2026-06-18","current":20.901261,"twenty":17.493192,"median":20.015847,"eighty":20.650154,"marketCap":15823421326.33},{"date":"2026-06-26","current":21.595968,"twenty":17.496103,"median":20.061717,"eighty":20.767009,"marketCap":16281617755.86},{"date":"2026-07-02","current":21.507343,"twenty":17.504259,"median":20.064683,"eighty":20.784032,"marketCap":16222688501.02},{"date":"2026-07-10","current":21.544508,"twenty":17.526194,"median":20.082188,"eighty":20.821212,"marketCap":16271827884.13},{"date":"2026-07-17","current":21.936175,"twenty":17.541814,"median":20.087829,"eighty":20.898969,"marketCap":16718811747.19},{"date":"2026-07-24","current":22.07626,"twenty":17.564926,"median":20.116937,"eighty":20.951,"marketCap":16761941188.16},{"date":"2026-07-31","current":21.66744,"twenty":17.586675,"median":20.124404,"eighty":21.004011,"marketCap":16545696607.24},{"date":"2026-08-07","current":20.666833,"twenty":17.604226,"median":20.156816,"eighty":21.026741,"marketCap":15758445214.07},{"date":"2026-08-14","current":21.122954,"twenty":17.619883,"median":20.180562,"eighty":21.040346,"marketCap":15758083883.88},{"date":"2026-08-21","current":21.131815,"twenty":17.635291,"median":20.20188,"eighty":21.05159,"marketCap":15955602988.26}],"updateTime":1787540009893},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634821492","title":"Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2634821492","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634821492?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:30","pubTimestamp":1778506200,"startTime":"0","endTime":"0","summary":"-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated prof","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3291995/0/en/Acoramidis-Continues-to-Demonstrate-Disease-Modifying-Effects-in-ATTR-CM-Reducing-sTTR-Variability-and-Outpatient-Worsening-Heart-Failure.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360107325.USD","ATTR","LU2244417387.USD","LU0187121727.USD","BK4129","LU2298064838.USD","LU0689626769.HKD","LU2308191902.HKD","LU1861214812.USD","EMA","LU0124676726.USD","BK4081","CM","ACM","LU1939255532.USD","BK4516","LU2238339852.HKD","BK4207","LU1861219969.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285232","title":"Analysts Have Conflicting Sentiments on These Utilities Companies: Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285232","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634285232?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:40","pubTimestamp":1778499650,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Utilities sector with new ratings on Emera (EMA), PPL (PPL) and Algonquin Power & Utilities (AQN). Emer...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-ppl-ppl-and-algonquin-power-utilities-aqn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-utilities-companies-emera-ema-ppl-ppl-and-algonquin-power-utilities-aqn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BN8TJ469.HKD","LU0320765489.SGD","BK4208","LU2449327464.USD","LU0683600562.USD","IE00BLSP4452.SGD","LU0070302665.USD","IE00BBT3K403.USD","PPL","AQNB","LU1093756168.USD","AQN","IE00BLSP4239.USD","BK4081","EMA","LU0208291251.USD","BK4585","LU0787776722.HKD","LU1093756325.SGD","IE00BD4GTW91.USD","IE00BD4GTT62.SGD","BK4588","IE00BD4GTV84.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634780283","title":"Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2634780283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634780283?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:20","pubTimestamp":1778498424,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK7129","EMA.AU","EMA","06938","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634828842","title":"Press Release: Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2634828842","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634828842?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:00","pubTimestamp":1778497200,"startTime":"0","endTime":"0","summary":"-- Elraglusib oral tablet formulation to drive next-phase clinical. -- FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer. patients, with focus on metastatic melanoma, NSCLC, colorectal, and. pancreatic cancers with initiation planned for 2H 2026. To support this initiative, the Company recently received Investigational New Drug  clearance from FDA to conduct a Phase 1/2 study designed to demonstrate that a higher overall exposure to elraglusib can be achieved with the oral formulation compared to the IV formulation. The study will evaluate the safety and potential efficacy of the oral formulation as a monotherapy in solid tumor patients, including those with metastatic melanoma, NSCLC, colorectal, and pancreatic cancers, based on evidence of efficacy of the IV formulation in prior clinical studies and machine learning therapeutic target analyses.\"Advancing the elraglusib oral tablet is an important element to the success of our overall development strategy,\" sai","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4218","MTD","BK4139","BK4585","LU1721428933.USD","BK4567","BK4081","EMA","LU1093756325.SGD","LU2413666699.HKD","LU0347712357.USD","IE00BYQQ9H92.USD","BK4181","ACTU","LU2413666426.HKD","IE00BFXG0V08.USD","IND","PK","BK4533","BK4548","IE00B5TLWC47.USD","BK4588","BK4121","LU1093756168.USD","LU2211817866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634050407","title":"Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634050407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634050407?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:12","pubTimestamp":1778494370,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. Class H ( ($HK:6938) ) has provided an update. Suzhou Ribo Life Science has submitted a phase 2b clinical trial ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-vortosiran-with-ema-filing-for-phase-2b-vte-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/suzhou-ribo-advances-vortosiran-with-ema-filing-for-phase-2b-vte-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634840658","title":"Emera (EMA) Receives a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2634840658","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634840658?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:00","pubTimestamp":1778486409,"startTime":"0","endTime":"0","summary":"In a report released today, Michael Lonegan from Barclays maintained a Hold rating on Emera, with a price target of $52.00. According to TipRanks, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/emera-ema-receives-a-hold-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/emera-ema-receives-a-hold-from-barclays-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633535974","title":"Press Release: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633535974","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633535974?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:30","pubTimestamp":1778239800,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc.  , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent updates and financial results for the quarter ended March 31, 2026.\"We remain disappointed with the unanticipated outcome of the FLASH2  study,\" stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. \"Despite the fact that HyBryte  demonstrated statistically significant reductions in cutaneous T-cell lymphoma  lesions after 6 weeks treatment in the first FLASH study, a similar signal was not observed with 18 weeks of treatment in this study. Over the coming weeks, we will analyze the data to better determine why the study did not meet expectations. If there is any clarity gained from further analysis of the dataset, especially with respect to specific subsets of patients that may benefit from HyBryte therapy, then w","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","TM","BK4081","PIM","BK4604","BK4585","R","BK4168","BK4232","BK4022","BK4139","EMA","IDR","BK4588","SNGX","BK4099","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432748","title":"Emera Q1 Adjusted Earnings, Revenue Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432748","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432748?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236298,"startTime":"0","endTime":"0","summary":"Emera  reported Q1 adjusted earnings Friday of 1.37 Canadian dollars  per share, up from CA$1.28 a year earlier.Analysts polled by FactSet expected CA$1.20.Revenue for the quarter ended March 31 was CA$2.81 billion, up from CA$2.68 billion a year earlier.Three analysts polled by FactSet expected CA$2.42 billion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7129","EMA.AU","EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633843295","title":"Emera reports Q1 adjusted EPS $1.37 vs. $1.28 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2633843295","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633843295?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:13","pubTimestamp":1778235232,"startTime":"0","endTime":"0","summary":"“Emera (EMA) delivered a solid first quarter, with important regulatory outcomes, disciplined capital deployment and record results at Emera Energy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emera-reports-q1-adjusted-eps-1-37-vs-1-28-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emera-reports-q1-adjusted-eps-1-37-vs-1-28-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633543476","title":"Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2633543476","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633543476?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:10","pubTimestamp":1778235035,"startTime":"0","endTime":"0","summary":"Earnings Flash (EMA) Emera Posts Q1 Adjusted EPS CA$1.37, vs. FactSet Est of CA$1.20","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","CA","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633443443","title":"Emera Q1 Adj. EPS $1.00 Beats $0.89 Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633443443","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633443443?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:07","pubTimestamp":1778234873,"startTime":"0","endTime":"0","summary":"Emera (NYSE:EMA) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $0.89 by 12.36 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52402045/emera-q1-adj-eps-1-00-beats-0-89-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633460434","title":"Press Release: Emera Reports 2026 First Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633460434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633460434?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:06","pubTimestamp":1778234760,"startTime":"0","endTime":"0","summary":"Today, May 8, 2026, Emera Inc.   reported 2026 first quarter financial results .--  Delivered a 7% increase in adjusted earnings per share2 , with. $1.37 in Q1 2026, compared to $1.28 in Q1 2025, and reported EPS of $1.85. --  On track to deliver 2026 adjusted EPS2 growth above our earnings. Q1 2026 reported net income was $562 million, or $1.85 per common share, compared to net income of $583 million, or $1.96 per common share, in Q1 2025.In Q1 2026, the translation impacts of a stronger CAD on USD denominated earnings decreased adjusted net income by $17 million and decreased reported net income by $30 million, compared to the same period in 2025. These impacts include the effect of FX hedges used to mitigate translation risk of USD earnings, which are included in Corporate in the Other segment.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633434311","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434311","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633434311?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:00","pubTimestamp":1778234400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Alpha Metal Res                                  1Q      (.36)   7:30 AM. ·Plains All Am                                    1Q       .37    7:30 AM. ·Plains GP A                                     1Q       .46    7:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","CEVA","CHRS","FIS","ESNT","BCSF","ENB","AQN","BLNK","CGBD","CBLL","CVRX","DCGO","ENTA","ABCL","EXPI","BATRA","CLSK","CNTY","EMA","CEG","ACH","AMR","BAM","BCAX","B","EMBJ","CRCL","CLMT","AU","DDD","AMCX","ANIP","CERT","CLLS","DCBO","APC","APEI","CDRE","DCH","ALXO","AMTM","FIGR","ASRT","CINT","BATRK","FHTX","ACM","ASTS","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633552172","title":"CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633552172","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633552172?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184300,"startTime":"0","endTime":"0","summary":"Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290541/0/en/CAMP4-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633817649","title":"BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633817649","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633817649?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184060,"startTime":"0","endTime":"0","summary":"$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby net product revenue, with strong prescribing growth and patient persistence driving continued commercial mom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290504/0/en/BridgeBio-Reports-First-Quarter-2026-Financial-Results-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4215","EMA","MAA","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145418","title":"Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145418","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145418?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:05","pubTimestamp":1778151900,"startTime":"0","endTime":"0","summary":"1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M  40% Confirmed Objective Response Rate in Metastatic Serous Endometrial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289839/0/en/Iovance-Biotherapeutics-Highlights-Positive-First-Quarter-2026-Results-Business-Achievements-and-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","LU1894683264.USD","SG9999011746.SGD","IE00BJJMRY28.SGD","BK4139","IE00B19Z3581.USD","IND","LU0061475181.USD","BK4534","LU0359201612.USD","IE00BJJMRX11.SGD","LU1023057109.AUD","BK4550","LU0269904917.USD","LU1074936037.SGD","LU2133065610.SGD","BK4571","LU0149725797.USD","BK4531","LU1162221912.USD","EMA","LU0310800965.SGD","LU1430594728.SGD","LU1894683348.USD","TIL","BK4509","BK4081","LU0128525689.USD","MAA","LU0052756011.USD","UPS","IE0002270589.USD","LU0359202008.SGD","IE0004445015.USD","TME","01698","BK4552","IOVA","BK4585","BK4131","LU0320765489.SGD","LU0070302665.USD","LU2237438978.USD","LU0456842615.SGD","BK4563","IE00B7SZLL34.SGD","BK4108","LU0828238088.HKD","LU1585245621.USD","IE00B12V2V27.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633199391","title":"Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2633199391","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633199391?lang=en_us&edition=fundamental","pubTime":"2026-05-07 16:57","pubTimestamp":1778144220,"startTime":"0","endTime":"0","summary":"Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON)FDA Breakthrough Therapy and EMA PRIME desi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289657/0/en/Oculis-Announces-Agreement-with-FDA-on-a-Special-Protocol-Assessment-SPA-for-Optic-Neuritis-Registrational-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2271345857.HKD","EMA","LU2264538146.SGD","BK4588","LU0158827781.USD","LU1244550221.USD","LU1548497426.USD","LU0912757837.SGD","LU0006306889.USD","LU1861214812.USD","LU2357305700.SGD","LU0124384867.USD","LU0971096721.USD","LU1244550494.USD","LU0234570918.USD","LU2089283258.USD","BK4605","LU1074936037.SGD","LU0098860793.USD","LU1861220033.SGD","LU1989772840.SGD","BK4516","LU1162221912.USD","LU0795875086.SGD","LU2133065610.SGD","IE00BKVL7J92.USD","IE00BZ199S13.USD","LU0320765646.SGD","LU1989772923.USD","LU0158827948.USD","ON","LABU","LU1854103824.USD","IE00BFMHRM44.USD","LU0557290698.USD","LU2360107325.USD","BK4127","LU1244550577.SGD","LU1720051017.SGD","BK4007","IE00BZ1G4Q59.USD","LU1791710582.SGD","OCS","LU0267386448.USD","LU0882574139.USD","LU1861215975.USD","LU0106831901.USD","LU1978683503.SGD","LU0795875169.SGD","LU1363072403.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633591711","title":"Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2633591711","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633591711?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:02","pubTimestamp":1778097720,"startTime":"0","endTime":"0","summary":"Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3289308/0/en/Revolution-Medicines-Reports-First-Quarter-2026-Financial-Results-and-Update-on-Corporate-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","LU2357305700.SGD","IE00BFMHRM44.USD","LU0456854461.SGD","BK4195","LU1861214812.USD","LU1720051108.HKD","LU2298322129.HKD","BK4211","PFS","LU0724618433.USD","LU1861219969.SGD","LU1854103824.USD","BK4512","LU1861220033.SGD","LU0348723411.USD","ODD","BK4081","LU1548497426.USD","EMA","LU1978683503.SGD","LU0266512127.USD","BK4585","BK4097","LU1861215975.USD","BK4139","LU1854104046.USD","IE00BD6J9T35.USD","IE00BZ199S13.USD","BK4605","IE0009354923.USD","CRC","BK4183","ON","BK4588","BMS","LU2065732104.USD","BK4141","BK4213","LU2360107325.USD","LU0124384867.USD","PRGS","RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633651649","title":"Press Release: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633651649","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633651649?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:10","pubTimestamp":1777925400,"startTime":"0","endTime":"0","summary":"Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ; majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-nave, highlighting continued momentum in the first-line setting. Presented newly updated clinical data demonstrating IBTROZI's impressive durability of response and progression-free survival in TKI-nave and TKI-pretreated patients with advanced ROS1-positive  non-small cell lung cancer  at AACR 2026. Announced acquisition of Japan rights to safusidenib from Daiichi Sankyo, enabling global development and commercialization of promising investigational medicine. Strong balance sheet with cash, cash equivalents, and marketable securities of $533.7 million as of March 31, 2026. NEW YORK, May 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2026, an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4585","BK4135","MAA","BK4007","BK4212","BK4081","EMA","CNS","BK4232","BK4588","R","BK4022","BK4215","DDC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632495887","title":"BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2632495887","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632495887?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:30","pubTimestamp":1777894200,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., May  04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic condi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286590/0/en/BridgeBio-to-Present-New-Acoramidis-Data-on-Disease-Progression-Biomarkers-and-Clinical-Outcomes-at-ESC-Heart-Failure-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}